TCGA-A7-A26E-01B-06R-A277-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 32
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.390
- MITOTIC_SPINDLE+0.140
- TGF_BETA_SIGNALING+0.130
- HEDGEHOG_SIGNALING+0.080
- PROTEIN_SECRETION+0.080
- ANDROGEN_RESPONSE+0.050
- WNT_BETA_CATENIN_SIGNALING+0.030
- NOTCH_SIGNALING+0.020
- TNFA_SIGNALING_VIA_NFKB+0.020
- KRAS_SIGNALING_UP+0.010
Top 10 suppressed
- MYC_TARGETS_V2-0.690
- OXIDATIVE_PHOSPHORYLATION-0.550
- MYC_TARGETS_V1-0.520
- DNA_REPAIR-0.460
- CHOLESTEROL_HOMEOSTASIS-0.450
- E2F_TARGETS-0.440
- MTORC1_SIGNALING-0.440
- GLYCOLYSIS-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- UV_RESPONSE_UP-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.943 |
| 2 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.929 |
| 3 | TCGA-A7-A13G-01B-04R-A22O-07 | — | D | 0.928 |
| 4 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.920 |
| 5 | TCGA-E2-A15I-01A-21R-A137-07 | — | B | 0.918 |
| 6 | ba2b0b86-f7f1-47f7-b0fd-bec3f623febb | — | — | 0.917 |
| 7 | d1447a31-64bb-4e70-ae50-eeff7a605f38 | — | — | 0.915 |
| 8 | 62454053-936d-4f19-8522-6219c47bdd1c | — | — | 0.914 |
| 9 | TCGA-44-2665-01B-06R-A277-07 | — | cohortMD2 | 0.911 |
| 10 | AUR-AFKB-TTP1-A-10-0-R-A741-41 | — | D | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |